drugset / Trial / NCT00189306

Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

NCT00189306

Phase 3 Completed 169 enrolled Graceway Pharmaceuticals, LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.

Timeline

Start
2001-03
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 5 % Topical